Back to Peptides

Wolverine Stack

Well Studied

BPC-157 + TB-500 | Tissue Repair & Recovery Protocol

Dose BPC-157: 250-500 mcg per dose + TB-500: 2-2.5 mg per dose
Frequency BPC-157: 1-2x daily; TB-500: 2x per week (typically Monday/Thursday or Tuesday/Friday)
Cycle 4-8 weeks for injury recovery; shorter for maintenance
Storage Lyophilized powder: room temperature acceptable; Reconstituted: 2-8°C refrigerated for both peptides

Availability

Wolverine Stack is currently available through specialized research suppliers

Always verify third-party testing and certificates of analysis before purchasing research peptides.

Combines BPC-157 and TB-500 for synergistic tissue repair and recovery. 87.5% improvement in knee pain patients per Lee & Padgett 2021 study.

Mechanism of Action

BPC-157 increases actin production and modulates nitric oxide for vascular effects; TB-500 sequesters actin for cell migration; synergistic enhancement of fibroblast and immune cell movement to injury sites.

Key Benefits

  • Complementary healing mechanisms
  • 87.5% improvement in knee pain patients
  • Reduced inflammation and enhanced cell migration
  • Promotes angiogenesis and reduces scarring
Molecular Weight
N/A
Chain Length
N/A
Type
Peptide blend
Amino Acid Sequence
N/A

Complex or non-standard sequence format

Tissue Repair

  • Tendon & Ligament Healing

    Both peptides show evidence for accelerated repair; BPC-157 improved Achilles tendon healing in animal models.

  • Muscle Injury Recovery

    BPC-157 demonstrates enhanced muscle regeneration; TB-500 promotes cell migration essential for repair.

  • Joint Pain & Cartilage

    Lee & Padgett study showed 87.5% of knee pain patients improved with BPC-157/TB4 combination.

Wound Healing

  • Accelerated Wound Closure

    TB-500 Phase 2 trials showed approximately one month faster healing in ulcer patients.

Anti-Inflammatory

  • Inflammatory Cytokine Reduction

    Both peptides modulate inflammatory pathways through different mechanisms.

Subcutaneous injection recommended; most studied and effective route.

GoalDoseFrequencyRoute
General Recovery ProtocolBPC-157: 250mcg 2x/day + TB-500: 2mg 2x/weekBPC-157 daily, TB-500 twice weeklySubQ
Intensive Injury RecoveryBPC-157: 500mcg 2x/day + TB-500: 2.5mg 2x/weekBPC-157 daily, TB-500 twice weeklySubQ near injury site
Maintenance/Prevention ProtocolBPC-157: 250mcg 1x/day + TB-500: 2mg 1x/weekBPC-157 daily, TB-500 weeklySubQ

Reconstitution Instructions

Materials Needed:
  • BPC-157 vial (5mg)
  • TB-500 vial (2-5mg)
  • Bacteriostatic water
  • Insulin syringes (29-31 gauge)
  • Alcohol swabs
  1. 1 Reconstitute each peptide separately
  2. 2 BPC-157: Add 2mL BAC water to 5mg vial = 250mcg per 0.1mL
  3. 3 TB-500: Add 2mL BAC water to 5mg vial = 250mcg per 0.1mL
  4. 4 Inject slowly along vial wall; swirl gently—never shake
  5. 5 Store reconstituted peptides refrigerated at 2-8°C
  6. 6 Do NOT mix peptides in same syringe unless pre-made blend
  7. 7 Use separate injection sites if administering same day
Growth Hormone (HGH)

BPC-157 upregulates GH receptors; combined use may accelerate recovery.

synergistic
CJC-1295/Ipamorelin

GH secretagogues complement stack by increasing endogenous growth hormone.

synergistic
PEG-MGF

MGF activates satellite cells; combined mechanisms may enhance muscle recovery.

synergistic
GHK-Cu

Copper peptide promotes collagen; no negative interactions expected.

compatible
NSAIDs

BPC-157 shows protective effects against NSAID-induced damage; long-term effects unknown.

monitor
Corticosteroids

Steroids may counteract healing; BPC-157 shown to reverse some steroid-induced damage in models.

monitor
Anticoagulants

Both peptides promote angiogenesis; monitor for bleeding issues.

monitor
Chemotherapy Agents

Angiogenesis promotion could theoretically support tumor growth; contraindicated with cancer history.

avoid
Week 1-2

Possible reduction in acute inflammation and pain at injury sites

Week 2-4

Noticeable improvement in recovery between workouts; reduced soreness

Week 4-6

Significant improvement in chronic injuries; improved joint comfort

Week 6-8

Optimal healing effects; structural improvements in damaged tissues

Post-Cycle

Benefits may persist as healed tissue maintains integrity

Common Side Effects

  • Not extensively documented in human studies
  • Generally well-tolerated in available research

Stop Signs - Discontinue if:

  • Any unusual lumps, growths, or rapid tissue changes
  • Severe injection site reactions or infections
  • Signs of allergic reaction (rash, swelling, difficulty breathing)
  • Unexpected bleeding or bruising
  • Persistent headaches or vision changes
  • Any symptoms suggesting abnormal growth

Contraindications

  • ANY history of cancer or suspicious growths
  • Active malignancy or concurrent chemotherapy
  • Pregnancy or breastfeeding

Good Signs

  • White or off-white lyophilized powder cake indicating proper freeze-drying
  • Crystal clear solution after reconstitution with bacteriostatic water
  • Certificate of Analysis with HPLC purity testing (>98%) and mass spectrometry verification

Warning Signs

  • Minor clumping acceptable if dissolves completely with gentle swirling

Bad Signs

  • Collapsed, yellowed, or powder stuck to vial sides—may indicate degradation from heat
  • Persistent cloudiness or visible particles after reconstitution—indicates contamination or degradation
  • BPC-157 + TB4 Knee Pain Study (Lee & Padgett)
    (2021)

    16 patients, intra-articular injection: Overall 87.5% (14/16) experienced knee pain relief. BPC-157 alone: 91.6% improvement (11/12). BPC-157 + TB4 combination: 75% improvement (3/4).

  • BPC-157 Systematic Review (Vasireddi et al.)
    (2025)

    36 articles reviewed. Preclinical models showed improvements in muscle tears, tendon ruptures, ligament tears, and fracture healing. Mechanism involves enhanced GH receptor expression and angiogenesis.

  • Thymosin β4 Clinical Wound Healing (Treadwell et al.)
    (2012)

    Two Phase 2 clinical trials showed thymosin β4 accelerated wound healing by approximately one month in responsive ulcer patients.

  • Thymosin β4 Regenerative Properties Review (Goldstein et al.)
    (2012)

    Comprehensive review establishing thymosin β4 as regenerative, promoting cell migration, reducing inflammation/apoptosis, and decreasing scar formation.

  • BPC-157 Achilles Tendon Healing
    (2003)

    Rats, 10 μg/kg i.p. daily, 14 days: BPC-157 demonstrated superior healing of transected Achilles tendons with improved biomechanical properties.

  • Thymosin β4 Wound Healing Acceleration
    (1999)

    Rats, full thickness wounds: Topical or intraperitoneal Tβ4 increased re-epithelialization by 42% at 4 days and up to 61% at 7 days.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.